₹1842.3
-1.42% today
· 30d +0.64%
as of 2026-09-04
Price · Daily Candles
“Laurus Labs sees DII investment surge as share price leaps over 100% in a year.”
Laurus Labs delivered a stellar Q4 2026 with net profit up 21.19% YoY to ₹282 Cr and annual net profit soaring 148.41% to ₹890 Cr. The stock has mirrored this success, delivering 110.03% returns over the last year, pushing its price-to-earnings (TTM) to 89.43, significantly above its median target of ₹1130.0.
BULL CASE
+Annual net profit for FY26 surged 148.41% YoY to ₹890 Cr.
+Q4 2026 net profit increased by 21.19% YoY to ₹282 Cr, with revenue up 5.31% to ₹1812 Cr.
+Laurus Labs delivered a strong 1-year return of 110.03% and a 3-month return of 41.34%.
+Operating profit margin (OPM) improved by 1.8% YoY in Q4 2026.
+Machine learning models predict strong sales growth, with ranks of 0.906 for recent 2-year and 0.858 for rolling 4-year periods.
BEAR CASE
−The current TTM PE of 89.43 is considerably higher than the forward PE of 61.58, indicating expectations for future growth are already priced in.
−The stock is trading at ₹1474.0, which is above the highest analyst target of ₹1370.0, suggesting potential overvaluation.
−Compared to peers like Sun Pharma (PE 41.7) and Cipla (PE 30.37), Laurus Labs' PE of 89.43 appears stretched.
−While EBIT growth predictions are strong (ranks >0.7), Free Cash Flow (FCF) growth predictions are weak (rolling 4-year rank 0.18, stable 7-year rank 0.154).
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹1812 Cr
+5.31% YoY
NET PROFIT
₹282 Cr
+21.19% YoY
OPM
28.73%
+1.8pp YoY
EPS
₹5.17
PE 89.43
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-22.4%, h2=-17.0%, h3=-20.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Laurus Labs, with a TTM PE of 89.43 and a ROCE of 18.0%, trades at a premium to peers like Sun Pharma (PE 41.7, ROCE 22.46%) and Cipla (PE 30.37, ROCE 25.09%) despite lower profitability metrics.
PEERPEROCE %
LAURUSLABS89.4318.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
76
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
STRONG
100
Valuation
STRETCHED
20
Growth
STRONG
91
Profitability
HIGH
85
Technicals
STRONG
70
Risk
LOW
90
Key Stats
TTM PE
89.43
P/B
15.05
52W HIGH
₹1949.0
OFF HIGH
-5.47%
DIV YIELD
0.16%
MKT CAP
₹99554 Cr
◉ Active Signals
MACDNeutral-10.4834
RSI(14)Neutral55.32
Street Consensus
13 analysts₹1055.15
mean target
Low ₹510.0Now ₹1842.3High ₹1370.0
⧉ Strategy Fit 🔒